[ad_1]
The vaccine that the French company Sanofi is developing for Covid-19 and that it intends to launch in June 2021 will not need a freezer for its maintenance, the president of the pharmaceutical industry, Olivier Bogillo, announced today in statements to CNews.
Unlike the American Pfizer and German BioNTech vaccines, which precede testing but need very low temperatures to stay (-70 ° C) “our vaccine will be like the flu, you can put it in the fridge,” Bogiyo told the channel. He explained that for this reason it would have an advantage “in some countries.”
The vaccine could be distributed as of June 2021. Phase 2 test results will be announced in early December and are currently “not negative,” he added.
If the results are positive, Sanofi will initiate the third phase of the clinical trial “in tens of thousands of patients” and “run the risk” of starting production at the same time. The results of the third phase will be announced in May. The company does not yet know if it will take one or two installments to be effective.
“The goal is to reach the end of 2021 with one billion doses. In 2022 we could even increase production to exceed that figure,” said the president of Sanofi France. The vaccines will be produced mainly in France, at the Vitriès-sur-Seine plant near Paris.
More than 35 vaccines for Covid-19 are currently being developed, of which 11 have entered the third phase of testing, the last before being licensed. The Pfizer / BioNTech association has announced that its vaccine is 90% effective, after having tested it in more than 40,000 people. Its goal is to deliver 300 million installments by April 2021.
“Pfizer is ‘slightly ahead,'” Bogiyo admitted, “but one laboratory alone cannot provide the quotas for the entire planet. We will need to have a lot of winners at the end of this race,” he said.
Bogiyo also said that the Sanofi vaccine will be available at an “affordable” price, without elaborating.
SOURCE: ΑΠΕ-ΜΠΕ
